Zydus Lifesciences launches generic bladder-treatment tablet in USA

23 Apr 2024 , 01:02 PM

Zydus Lifesciences announced on Monday that it has introduced a generic drug to treat overactive bladder in the United States. Zydus Lifesciences announced in a regulatory filing that Mirabegron extended-release tablets in the strength of 25 mg have been released in the US market following final FDA approval.

Zydus was among the initial companies to introduce the generic variant of Mirabegron extended-release tablets (USP 25 mg) in the U.S. market. The company is also ready to release the 50 mg tablets to the market, it said.

Mirabegron is used to treat Overactive Bladder (OAB) with symptoms such as urge urine incontinence, urgency, and urinary frequency. The medicine will be made at the Zydus group’s formulation production facility in India’s Ahmedabad Special Economic Zone, according to the manufacturer.

Punit Patel, CEO of Zydus Americas, stated that the launch of generic Mirabegron will increase access and availability of the pharmaceutical for patients in the United States.

“This is a significant launch for us which will strengthen our growth plans in the US market in the current fiscal,” he went on to say.

According to IQVIA MAT data, Mirabegron extended-release tablets (USP 25mg and 50mg) had yearly sales of USD 2.42 billion in the United States.

Zydus Lifesciences Limited, previously named Cadila Healthcare Limited, stands as a prominent player in the Indian pharmaceutical sector, offering comprehensive healthcare solutions worldwide. Leveraging extensive knowledge in healthcare, it possesses robust capabilities across all aspects of the pharmaceutical industry.

At around 11.14 AM, Zydus Lifesciences was trading 1.23% lower at ₹947.90, against the previous close of ₹959.70 on NSE. The counter touched an intraday high and low of ₹968.05, and ₹944.60, respectively.

For feedback and suggestions, write to us at [e-mail]